ZURA · Zura Bio Limited Class A Ordinary Shares
View on chartInsiders & Stakes
| AI Biotechnology LLC | ▲ Buy | Open Market | 6,552,725 Shares held | 2/26/2026 | View profile |
| Sidhu Someit Chief Executive Officer | ▼ Sell | Open Market | 2,085,418 Shares held | 9/4/2024 | View profile |
| JATT Ventures, L.P. 10% Owner | ▼ Sell | Other | 967,370 Shares held | 2/10/2023 | View profile |
| Amit Munshi Director | ▲ Buy | Open Market | 777,384 Shares held | 4/22/2024 | View profile |
| Christopher Cabell President & Head of R&D | ▲ Buy | Grant | 162,060 Shares held | 5/18/2023 | View profile |
| Howell Michael See Remarks | ▼ Sell | Tax Withholding | 104,535 Shares held | 5/18/2024 | View profile |
| Ploos van Amstel Arnout | ▲ Buy | Open Market | 100,000 Shares held | 5/17/2024 | View profile |
| Nistala Kiran Executive Vice President | ▲ Buy | Open Market | 3,195 Shares held | 4/22/2024 | View profile |
| Kim Davis Chief Legal Officer | ▲ Buy | Grant | 1,500 Shares held | 9/16/2024 | View profile |
| Thiara Parvinder Director | ▼ Sell | Open Market | 0 Shares held | 11/25/2024 | View profile |
| Owl Creek Asset Management, L.P. 10% Owner | ▼ Sell | Other | 0 Shares held | 3/20/2023 | View profile |
Transaction History
| AI Biotechnology LLC | ▲ Buy | Open Market | 2,000,000 | $12.5M | 2/26/2026 |
| Thiara Parvinder | ▼ Sell | Open Market | 1,001,633 | $2.7M | 11/25/2024 |
| Kim Davis | ▲ Buy | Grant | 1,000 | $0 | 9/16/2024 |
| Thiara Parvinder | ▼ Sell | Open Market | 3,800,000 | $10.3M | 9/11/2024 |
| Sidhu Someit | ▼ Sell | Open Market | 51,728 | $200K | 9/4/2024 |
| Howell Michael | ▼ Sell | Tax Withholding | 9,860 | $60K | 5/18/2024 |
| Ploos van Amstel Arnout | ▲ Buy | Open Market | 80,000 | $496K | 5/17/2024 |
| Howell Michael | ▲ Buy | Open Market | 7,987 | $25K | 4/22/2024 |
| Nistala Kiran | ▲ Buy | Open Market | 3,195 | $10K | 4/22/2024 |
| Amit Munshi | ▲ Buy | Open Market | 159,744 | $500K | 4/22/2024 |
| Sidhu Someit | ▲ Buy | Open Market | 1,186,901 | $3.7M | 4/22/2024 |
| Thiara Parvinder | ▼ Sell | Open Market | 2,000,000 | $8.0M | 12/12/2023 |
| Kim Davis | ▲ Buy | Grant | 500 | $0 | 10/1/2023 |
| Amit Munshi | ▲ Buy | Open Market | 117,647 | $500K | 6/5/2023 |
| Kim Davis | ▲ Buy | Grant | 492,381 | $0 | 5/18/2023 |
| Christopher Cabell | ▲ Buy | Grant | 162,060 | $0 | 5/18/2023 |
| Howell Michael | ▲ Buy | Grant | 114,395 | $0 | 5/18/2023 |
| Owl Creek Asset Management, L.P. | ▼ Sell | Other | 550,000 | $5.7M | 3/20/2023 |
| Sidhu Someit | ▼ Sell | Other | 2,337,630 | — | 3/20/2023 |
| Sidhu Someit | ▼ Sell | Other | 2,337,630 | — | 2/10/2023 |
| JATT Ventures, L.P. | ▼ Sell | Other | 2,337,630 | — | 2/10/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains
Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains. Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.